Compare Canadian Natural Resources Ltd. (CNQ) vs Pfizer Inc (PFE) Price & Performance

CNQ trades at $43.05, up 2.97% today, with a bullish technical signal supported by moving averages and ADX. The stock shows strong fundamentals with a P/E of 11.8, net income margin of 24.5%, and consistent earnings beats in recent quarters. Recent news highlights its robust asset base and operational efficiency amid volatile oil markets. Cash flow remains positive, with 2025 net cash flow at $542 million.

Outlook is positive with analyst consensus strongly favoring Buy (75%), driven by valuation appeal and shareholder returns via dividends and buybacks. Key risks include oil price volatility and rising debt-to-asset ratio, which increased to 22.04% in 2024. The stock's proximity to its 52-week high suggests cautious optimism, but fundamentals support long-term growth potential.

Pfizer (PFE) trades at $24.25, up 0.33% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 EPS of $0.75, beating expectations, and maintains a dividend of $0.43 per share. Recent news highlights Pfizer's focus on its obesity and oncology pipeline, with key catalysts expected in 2026. Financials show revenue of $62.58B in 2025, with a net income margin of 11.83% and a P/E ratio of 18.69.

The outlook for Pfizer is mixed, with analyst consensus leaning toward Hold (58.98%) but a price target of $28.78 suggesting potential upside. Investment opportunities include a strong dividend yield and pipeline advancements, while risks involve patent cliffs and competitive pressures. The stock's current valuation appears reasonable, but execution on pipeline developments is critical for future growth.